Like many of his patients, Kerry Solomon, MD, enjoys playing golf, spending time at the beach, and staying active. Dr. Solomon strives to get the most out of life and understands that vision is paramount to doing so. This pursuit of independence and happiness led him to the Alcon AcrySof IQ PanOptix Trifocal IOL.
We all want to better interact with the world around us. If our vision is in check, it opens the doors to better living. For many of my patients, that means not needing glasses. As someone who is active, I see the value in that independence.
“I broke free from traditional PC-IOLs, and my patients have been enjoying the benefits ever since.”
Kerry Solomon, MD on Breaking Free:
Like many of his patients, Kerry Solomon, MD, leads an active lifestyle, so he values IOL technology with flexibility and options. In this video, Dr. Solomon describes how he broke free from tradition with the AcrySof IQ PanOptix Trifocal IOL by Alcon.
In Charleston where I practice, cataract patients are leading more active lives than ever before. They’re filling their days with much of the same activities that I enjoy. So when they come to me with certain visual expectations, I hear them.
Patients today tend to be less tolerant of visual disturbances and are looking for solutions that will allow them to be less dependent on their glasses.
After hearing the results from my patients that they were getting, even my fairly conservative partners started implanting the PanOptix IOL. And their patients are also happy.
“We’re all universally striving to live out our days in ways that fulfill us. With the PanOptix lens, I feel good knowing that I’m able to help my patients achieve greater freedom to do whatever they want to do.”
More surgeons on breaking free:
*Based on mean value of binocular defocus curve at near, intermediate and distance at 6 months (n=127).
†Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 ETDRS chart letters in the line were identified correctly.
1. AcrySof® IQ PanOptix® Directions for Use.
US-ACP-2000183
© 2020 Alcon Inc. 07/20
PanOptix is a trademark of Alcon. All other brand/product names are the trademarks of their respective owners.
AcrySof® IQ PanOptix® Family of Trifocal IOLs
IMPORTANT PRODUCT INFORMATION
CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.
INDICATIONS: The AcrySof® IQ PanOptix® Trifocal IOLs include AcrySof® IQ PanOptix® and AcrySof® IQ PanOptix® Toric and are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. In addition, the AcrySof® IQ PanOptix® Toric Trifocal IOL is indicated for the reduction of residual refractive astigmatism.
WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia and ensure that IOL centration is achieved.
For the AcrySof® IQ PanOptix® Toric Trifocal IOL, the lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction. If necessary, lens repositioning should occur as early as possible prior to lens encapsulation.
Some visual effects may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos or starbursts, as well as other visual symptoms. As with other multifocal IOLs, there is a possibility that visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. A reduction in contrast sensitivity as compared to a monofocal IOL may be experienced by some patients and may be more prevalent in low lighting conditions. Therefore, patients implanted with multifocal IOLs should exercise caution when driving at night or in poor visibility conditions.
Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning).
As with other multifocal IOLs, patients may need glasses when reading small print or looking at small objects. Posterior capsule opacification (PCO) may significantly affect the vision of patients with multifocal IOLs sooner in its progression than patients with monofocal IOLs. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure, available from Alcon, informing them of possible risks and benefits associated with the AcrySof® IQ PanOptix® Trifocal IOLs.
ATTENTION: Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings and precautions.
